Doctors may be able to predict the likelihood of postpartum depression, Johns Hopkins researchers believe, by using a blood test that screens for two mutated genes. They studied mice and 52 pregnant women to identify the epigenetic biomarkers in question.
In the fiercely competitive global stent market, Abbott seems to view size as mattering most.
EuroPCR kicked off in Paris on Tuesday, bringing devicemakers from around the globe together to unveil data and angle for attention from the continent's interventional cardiovascular specialists. Here's a look at some early highlights from the conference.
OrbusNeich Medical called the cops on Boston Scientific in Germany in a nasty escalation of their ongoing stent patent dispute.
Medtronic raked in $4.5 billion in revenue last quarter, riding a jump in international sales to 4% growth, but a spike in charges brought net profits down 2%.
It's time, once again: We want your nominations for this year's 15 fiercest private medical device and diagnostics developers.
Interleukin Genetics just got a $12 million shot in the arm, a private placement funding that will be crucial to its survival as a developer of genetic tests for chronic conditions.
According to AdvaMed, the user fees that industry players contribute to the FDA, money that currently helps the agency retain staff and support programs, may now take a hit to the tune of about $2.9 million.
Fresh off the launch its gene-expression cancer diagnostic, Seattle's NanoString is plotting an IPO worth up to $86.3 million, the company disclosed Monday.
The lengthy patent dispute between Medtronic and Boston Scientific will end in the nation's highest courtroom, as the Supreme Court has agreed to hear Medtronic's plea to avoid paying cardiac device royalties.
Covidien nailed down a 510(k) clearance, this time for a group of next-generation Nellcor pulse oximetry monitoring devices--a regulatory win that will likely help fuel continued robust growth in the line.
Medtronic snagged a CE mark for the Export Advance aspiration catheter, planning to launch the clot-removing device in Europe and other international markets.
Thousands of patients and regulators may believe otherwise, but attorneys representing 5 executives from the defunct breast-implant company Poly Implant Prothèse insisted last week that their clients did not knowingly make substandard implants.
In April, Abbott Laboratories announced it was yanking the FreeStyle InsuLinx blood glucose meters off the U.S. market, and now the FDA has assigned its most-serious Class I label to the effort, warning that the devices' malfunction could lead to serious injury or death.
Students at Rice University have created a shoe-mounted pump that uses the wearer's own motion to generate energy needed to operate medical devices.
Vascular Solutions is suing Boston Scientific, claiming the company's Guidezilla extension catheter infringes on its patents and asking a Minnesota court to hault the device's sale.
Thoratec scored the FDA's blessing to market a next-generation controller for the HeartMate II implant, giving the company a user-friendly face for its market-leading left ventricular assist device.
Quest Diagnostics is on a buying spree to grow its testing business, and now the company has signed a deal to buy the toxicology and clinical laboratory segment of health insurance giant Humana.
Tryton Medical won a CE mark for a short version of its Side Branch Stent to treat bifurcated lesions, a crucial step toward reaching more patients and pursuing the company's U.S. approval pathway.
Johnson & Johnson has had enough with metal-on-metal and ceramic-on-metal hips, disclosing that it will leave those business lines entirely behind by the end of 2014.